The following information is intended as a resource for journalists only and was factually correct at the time it was issued.

Follow AbbVie UK


HUMIRA® (adalimumab) 80 mg/0.8 mL Presentation intended as an Alternative Option for Therapy Induction and Maintenance Therapy is Now Available

Press releases   •   Dec 03, 2018 09:25 GMT

• HUMIRA citrate-free 80 mg/0.8 mL formulation reduces the number of injections required to initiate HUMIRA therapy by half • Convenient 80 mg every other week dosing for patients that require dose escalation

New Presentation, HUMIRA® (adalimumab) 20 mg/0.2 mL for Injection in Pre-filled Syringe (PFS) Launched for Paediatric Patients, together with the Introduction of Fixed Weight Dosing

Press releases   •   Mar 29, 2018 16:06 BST

Maidenhead, UK, 29th March 2018 – AbbVie a global research and development-based biopharmaceutical company, today announced the launch of HUMIRA® (adalimumab) 20 mg/0.2 mL presentation. The presentation is designed for injection in a pre-filled syringe specifically in paediatric patients for approved indications.